ArticleBiomolecules2025
Proteomic Profiling of Inflammatory Protein Dysregulation in HLA-B27-Positive Ankylosing Spondylitis: Molecular Signatures and Potential Biomarkers.
Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Longitudinal proteomic analysis of GCF in regenerative healing of molar furcation degree II defects treated with OFD, EMD, or A-PRF + : a pilot study.Scientific reports · 2026Trial
- Association of Low Free T3 with Disease Presence and Activity in Ankylosing Spondylitis.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study explored the proteomic landscape of inflammatory protein dysregulation in ankylosing spondylitis (AS), a chronic inflammatory disorder primarily affecting the axial skeleton and strongly associated with the HLA-B27 allele, particularly the HLA-B2705 and HLA-B2704 subtypes prevalent in Chinese populations. Blood samples from HLA-B27-positive AS patients and normal controls (NC) were analyzed using the Olink Target 96 inflammation panel to profile 92 inflammatory proteins. HLA-B27 subtyping was performed via PCR-SSP. To identify key proteins and stratify AS subtypes, we employed machine learning classifiers, including LightGBM models coupled with SHAP value interpretation, alongside traditional statistical analyses. The proteomic analysis revealed significant dysregulation of pro-inflammatory cytokines, such as IL-6 and IL-17A, in AS patients compared to NC, with CXCL9 and NRTN identified as potential biomarkers associated with disease activity. The combination of LightGBM classifiers and traditional statistical methods demonstrated high accuracy in distinguishing AS from NC and effectively stratifying subtypes. These findings provide valuable insights into the inflammatory mechanisms underlying AS pathogenesis and highlight potential biomarkers and therapeutic targets for improving diagnosis and treatment strategies. Future studies with larger and more diverse cohorts, as well as longitudinal designs, are warranted to validate these biomarkers and elucidate their dynamic changes during disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.